Skip to main content
. 2015 Feb 10;9:20. doi: 10.3389/fncel.2015.00020

Figure 3.

Figure 3

The susceptibility to PTZ-induced seizures was reduced after intra-hippocampal administration of TRPV1 agonist and antagonist in a dose-dependent manner. (A) The latency to TCS was significantly delayed in hippocampal administration of 33 nmol/μL/side CAP, 33 nmol/μL/side CPZ groups compared with the vehicle group. The 10, 100 nmol/μL/side CAP; 10, 100 nmol/μL/side CPZ, and ESM had no effect on the latency to TCS. (B) Similarly, the maximum grades of seizure were significantly reduced by 33 nmol/μL/side CAP, and 10, 33 nmol/μL/side CPZ except 10, 100 nmol/μL/side CAP, 100 nmol/μL/side CPZ, and ESM compared with the vehicle group. (C) Decreased mortality in 33 nmol/μL/side CAP and 10, 33 nmol/μL/side CPZ groups. However, the mortality were not changed by 10, 100 nmol/μL/side CAP, 100 nmol/μL/side CPZ, and ESM administration. All data are expressed as mean ± SEM. *p < 0.05. **p < 0.01. ***p < 0.001.